OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Acute myeloid leukemia

Menin inhibitors, FLT3 and IDH combinations, venetoclax backbones and what comes after.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:09 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.

Phase advances
2
since 2026-07-14
New Ph2+ trials
12
Results posted
3
Readouts due
10
primary completion reached
Trial papers
16
PubMed, last 60 days
  1. New trial
    New Ph1 trial: NCT07929740

    Kura Oncology, Inc.. Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS

  2. Phase advance
    Palbociclib advances to Ph1/Ph2 (indication level)

    Second Affiliated Hospital of Nanchang University posted NCT07926607: Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

  3. New trial
    New Ph1/Ph2 trial: NCT07926607

    Second Affiliated Hospital of Nanchang University. Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

  4. New trial
    New Ph2 trial: NCT07925554

    Peking University People's Hospital. Interferon-α Maintenance in Favorable-Risk AML

  5. New trial
    New Ph3 trial: NCT07925190

    Beijing InnoCare Pharma Tech Co., Ltd.. A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients

  6. New trial
    New Ph1 trial: NCT07923071

    Syndax Pharmaceuticals. A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment

  7. New trial
    New Ph1 trial: NCT07914556

    Mabwell (Shanghai) Bioscience Co., Ltd.. Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers

  8. Paper
  9. New trial
    New Ph1 trial: NCT07909733

    University of Wisconsin, Madison. Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT

  10. Paper
  11. Readout due
    Readout due: NCT03121014 reached primary completion

    University of Illinois Chicago. Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

  12. New trial
    New Ph1 trial: ADVANCE-01 (NCT07905027)

    Seattle Children's Hospital. A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML

  13. New trial
    New Ph1 trial: NCT07897136

    Liping Dou. CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia

  14. Paper
  15. Results posted
    Results posted: NCT06508489

    A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

  16. Paper
  17. New trial
    New Ph1/Ph2 trial: Dual CARCIK (NCT07877610)

    Fondazione Matilde Tettamanti Menotti De Marchi Onlus. CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults

  18. New trial
    New Ph2 trial: NCT07874737

    The Affiliated People's Hospital of Ningbo University. Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia

  19. Results posted
    Results posted: NCT05656248

    Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

  20. New trial
    New Ph1/Ph2 trial: NCT07873827

    Stemline Therapeutics, Inc.. KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies

  21. Results posted
    Results posted: NCT06679582

    Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

  22. Readout due
    Readout due: NCT04062266 reached primary completion

    M.D. Anderson Cancer Center. AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

  23. Paper
  24. Paper
  25. Paper
    Menin inhibitors in acute leukemia: Advances and future directions.

    Nasiri A, Saleh MFM, Alfayez M et al. Hematology/oncology and stem cell therapy.

    Publisher page
  26. Paper
  27. Readout due
    Readout due: IDH1-AML-2024 reached primary completion

    Institute of Hematology & Blood Diseases Hospital, China. Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

  28. Paper
  29. Readout due
    Readout due: NCT07163793 reached primary completion

    Northwell Health. Pilot Study of Reduced Venetoclax Exposure

  30. Paper
  31. Paper
  32. Paper
  33. Paper
    Effects of a symptom voice diary intervention program in patients with acute leukemia: a randomized controlled trial.

    Li Z, Li C, Fang X et al. European journal of oncology nursing : the official journal of European Oncology Nursing Society.

    Publisher page
  34. Readout due
    Readout due: NCT06704152 reached primary completion

    BlueSphere Bio, Inc. BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

  35. Paper
  36. Readout due
    Readout due: MORE reached primary completion

    Franziska Wachter. A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

  37. Readout due
    Readout due: NCT02392572 reached primary completion

    M.D. Anderson Cancer Center. ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

  38. Readout due
    Readout due: NCT06379360 reached primary completion

    The First Affiliated Hospital of Soochow University. Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

  39. Phase advance
    Granulocyte Colony-Stimulating Factor advances to Ph3 (indication level)

    Ruijin Hospital posted NCT07735117: Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML

  40. Paper
  41. Readout due
    Readout due: NCT03672539 reached primary completion

    M.D. Anderson Cancer Center. Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

  42. Readout due
    Readout due: NCT05589896 reached primary completion

    Ossium Health, Inc.. A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.